This is from the non-Dechert and non-RS portion of the Blog.
We used to post about defense wins in litigation over both branded and generic ranitidine fairly often. The MDL in the Southern District of Florida systematically knocked down all of plaintiffs’ theories based on the lack of legal support (e.g., preemption) and lack of